These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21479096)

  • 1. Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy.
    Hutchinson E; Droti B; Gibb D; Chishinga N; Hoskins S; Phiri S; Parkhurst J
    Bull World Health Organ; 2011 Apr; 89(4):312-6. PubMed ID: 21479096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Level of understanding of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative analysis.
    Okwera A; Mafigiri DK; Guwatudde D; Whalen C; Joloba M
    Afr Health Sci; 2015 Mar; 15(1):49-57. PubMed ID: 25834530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV.
    Date AA; Vitoria M; Granich R; Banda M; Fox MY; Gilks C
    Bull World Health Organ; 2010 Apr; 88(4):253-9. PubMed ID: 20431788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of health policy in Malawi: the influence of context, evidence and links in the creation of a national policy for cotrimoxazole prophylaxis.
    Hutchinson E
    Malawi Med J; 2011 Dec; 23(4):109-14. PubMed ID: 23451562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Operational research in Malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV.
    Harries AD; Zachariah R; Chimzizi R; Salaniponi F; Gausi F; Kanyerere H; Schouten EJ; Jahn A; Makombe SD; Chimbwandira FM; Mpunga J
    BMC Public Health; 2011 Jul; 11():593. PubMed ID: 21794154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-associated tuberculosis epidemic--when will we act?
    Harries AD; Zachariah R; Corbett EL; Lawn SD; Santos-Filho ET; Chimzizi R; Harrington M; Maher D; Williams BG; De Cock KM
    Lancet; 2010 May; 375(9729):1906-19. PubMed ID: 20488516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expanding role of co-trimoxazole in developing countries.
    Church JA; Fitzgerald F; Walker AS; Gibb DM; Prendergast AJ
    Lancet Infect Dis; 2015 Mar; 15(3):327-39. PubMed ID: 25618179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
    Crook AM; Turkova A; Musiime V; Bwakura-Dangarembizi M; Bakeera-Kitaka S; Nahirya-Ntege P; Thomason M; Mugyenyi P; Musoke P; Kekitiinwa A; Munderi P; Nathoo K; Prendergast AJ; Walker AS; Gibb DM;
    BMC Med; 2016 Mar; 14():50. PubMed ID: 27004529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial.
    Wiktor SZ; Sassan-Morokro M; Grant AD; Abouya L; Karon JM; Maurice C; Djomand G; Ackah A; Domoua K; Kadio A; Yapi A; Combe P; Tossou O; Roels TH; Lackritz EM; Coulibaly D; De Cock KM; Coulibaly IM; Greenberg AE
    Lancet; 1999 May; 353(9163):1469-75. PubMed ID: 10232312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.
    Zachariah R; Harries AD; Luo C; Bachman G; Graham SM
    Lancet Infect Dis; 2007 Oct; 7(10):686-93. PubMed ID: 17897611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Escherichia coli resistance to co-trimoxazole in tuberculosis patients and in relation to co-trimoxazole prophylaxis in Thyolo, Malawi.
    Zachariah R; Harries AD; Spielmann MP; Arendt V; Nchingula D; Mwenda R; Courtielle O; Kirpach P; Mwale B; Salaniponi FM
    Trans R Soc Trop Med Hyg; 2002; 96(2):202-4. PubMed ID: 12055816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis with co-trimoxazole for HIV infected adults in Africa.
    Anglaret X; Eholie S
    BMJ; 2008 Jul; 337():a304. PubMed ID: 18614521
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of co-trimoxazole for urinary tract infections in developing countries.
    Leblebicioglu H; Ozaras R; Sunbul M
    Lancet Infect Dis; 2015 Jul; 15(7):764-5. PubMed ID: 26122444
    [No Abstract]   [Full Text] [Related]  

  • 14. Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation.
    Harries AD; Lawn SD; Suthar AB; Granich R
    Lancet Infect Dis; 2015 Dec; 15(12):1492-6. PubMed ID: 26515525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
    Yazdanpanah Y; Losina E; Anglaret X; Goldie SJ; Walensky RP; Weinstein MC; Toure S; Smith HE; Kaplan JE; Freedberg KA;
    AIDS; 2005 Aug; 19(12):1299-308. PubMed ID: 16052085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.
    Saadani Hassani A; Marston BJ; Kaplan JE
    J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S257-69. PubMed ID: 25768865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing opportunistic infections among human immunodeficiency virus-infected adults in African countries.
    Grant AD; Kaplan JE; De Cock KM
    Am J Trop Med Hyg; 2001 Dec; 65(6):810-21. PubMed ID: 11791979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.
    Mermin J; Lule J; Ekwaru JP; Malamba S; Downing R; Ransom R; Kaharuza F; Culver D; Kizito F; Bunnell R; Kigozi A; Nakanjako D; Wafula W; Quick R
    Lancet; 2004 Oct 16-22; 364(9443):1428-34. PubMed ID: 15488218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
    Walker AS; Ford D; Gilks CF; Munderi P; Ssali F; Reid A; Katabira E; Grosskurth H; Mugyenyi P; Hakim J; Darbyshire JH; Gibb DM; Babiker AG
    Lancet; 2010 Apr; 375(9722):1278-86. PubMed ID: 20347483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.
    Suthar AB; Vitoria MA; Nagata JM; Anglaret X; Mbori-Ngacha D; Sued O; Kaplan JE; Doherty MC
    Lancet HIV; 2015 Apr; 2(4):e137-50. PubMed ID: 26424674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.